Jan 5, 2026
What serious adverse event signals (pancreatitis, thyroid, eye) have been reported for tirzepatide in FAERS and EudraVigilance, and how should clinicians interpret disproportionality findings?
Post-marketing pharmacovigilance analyses of tirzepatide identify disproportionate reporting for pancreato-biliary events (including pancreatitis), thyroid-related events, and eye-related events acros...